目的:系统分析黄甲软肝颗粒及其中间体的化学成分,阐明其复方新药的化学物质基础。方法:采用超高效液相色谱-飞行时间串联质谱(UHPLC-Q-TOF-MS)技术,离子源为ESI,色谱条件:Agilent Zorbax Eclipse Plus C_(18)色谱柱(2.1mm×150mm,...目的:系统分析黄甲软肝颗粒及其中间体的化学成分,阐明其复方新药的化学物质基础。方法:采用超高效液相色谱-飞行时间串联质谱(UHPLC-Q-TOF-MS)技术,离子源为ESI,色谱条件:Agilent Zorbax Eclipse Plus C_(18)色谱柱(2.1mm×150mm,1.8μm),流动相为0.1%甲酸水溶液(A)-0.1%甲酸乙腈(B),洗脱梯度:0~20min,3%~60%B;20min~25min,60%~95%B;25min~30min,95%B;30min~31min,95%~3%B;31min~35min,3%B,流速0.35mL·min^(-1),柱温35℃,进样量1μL。质谱分析采用正、负离子模式扫描,扫描范围m/z100~1700。通过与自建化学成分数据库比对(部分对照品验证)后对各离子峰进行鉴定。结果:从黄甲软肝颗粒中共鉴定出126个化学成分,黄甲软肝中间体中共鉴定出141个化学成分,包括有机酸类、酚酸类、黄酮类、三萜类、皂苷类等。结论:建立的UHPLC-TOF-MS分析方法,结合数据库匹配,可全面快速地分析黄甲软肝颗粒及中间体中的化学成分,为其组方药效物质基础及质量控制研究提供科学依据。展开更多
Pharmacodynamics material basis and effective mechanisms are the two main issues to decipher the mechnisms of action of Traditional Chinese medicines(TCMs)for the treatment of diseases.TCMs,in“multi-component,multi-t...Pharmacodynamics material basis and effective mechanisms are the two main issues to decipher the mechnisms of action of Traditional Chinese medicines(TCMs)for the treatment of diseases.TCMs,in“multi-component,multi-target,multi-pathway”paradigm,show satisfactory clinical results in complex diseases.New ideas and methods are urgently needed to explain the complex interactions between TCMs and diseases.Network pharmacology(NP)provides a novel paradigm to uncover and visualize the underlying interaction networks of TCMs against multifactorial diseases.The development and application of NP has promoted the safety,efficacy,and mechanism investigations of TCMs,which then reinforces the credibility and popularity of TCMs.The current organcentricity of medicine and the“one disease-one target-one drug”dogma obstruct the understanding of complex diseases and the development of effective drugs.Therefore,more attentions should be paid to shift from“phenotype and symptom”to“endotype and cause”in understanding and redefining current diseases.In the past two decades,with the advent of advanced and intelligent technologies(such as metabolomics,proteomics,transcriptomics,single-cell omics,and artificial intelligence),NP has been improved and deeply implemented,and presented its great value and potential as the next drug-discovery paradigm.NP is developed to cure causal mechanisms instead of treating symptoms.This review briefly summarizes the recent research progress on NP application in TCMs for efficacy research,mechanism elucidation,target prediction,safety evaluation,drug repurposing,and drug design.展开更多
中药复方药效物质基础(material basis for efficacy of Chinese herbal formula)的是目前亟待解决的中药领域的关键问题之一,而目前对中药复方药效物质基础的界定,学术界尚有分歧。中药复方药效物质基础是某一特定复方经与人体作用后...中药复方药效物质基础(material basis for efficacy of Chinese herbal formula)的是目前亟待解决的中药领域的关键问题之一,而目前对中药复方药效物质基础的界定,学术界尚有分歧。中药复方药效物质基础是某一特定复方经与人体作用后在发挥疗效的特异性的靶器官、靶组织中达到一定浓度并发挥生物学效应的直接或间接来源于该复方的非内源性活性物质的总和。中药复方药效物质基础的系统药理学评价是中药现代化和国际化的核心与基石,而中药质量控制是中药复方药效物质基础的系统药理学评价的先决条件。展开更多
文摘目的:系统分析黄甲软肝颗粒及其中间体的化学成分,阐明其复方新药的化学物质基础。方法:采用超高效液相色谱-飞行时间串联质谱(UHPLC-Q-TOF-MS)技术,离子源为ESI,色谱条件:Agilent Zorbax Eclipse Plus C_(18)色谱柱(2.1mm×150mm,1.8μm),流动相为0.1%甲酸水溶液(A)-0.1%甲酸乙腈(B),洗脱梯度:0~20min,3%~60%B;20min~25min,60%~95%B;25min~30min,95%B;30min~31min,95%~3%B;31min~35min,3%B,流速0.35mL·min^(-1),柱温35℃,进样量1μL。质谱分析采用正、负离子模式扫描,扫描范围m/z100~1700。通过与自建化学成分数据库比对(部分对照品验证)后对各离子峰进行鉴定。结果:从黄甲软肝颗粒中共鉴定出126个化学成分,黄甲软肝中间体中共鉴定出141个化学成分,包括有机酸类、酚酸类、黄酮类、三萜类、皂苷类等。结论:建立的UHPLC-TOF-MS分析方法,结合数据库匹配,可全面快速地分析黄甲软肝颗粒及中间体中的化学成分,为其组方药效物质基础及质量控制研究提供科学依据。
基金the Natural Science Foundation of Zhejiang Province(No.LZ20H290002)the Innovation Team and Talents Cultivation Program of the National Administration of Traditional Chinese Medicine(No.ZYYCXTD-D-202002)+2 种基金the Fundamental Research Funds for the Central Universities(No.226-2022-00226)the Science and Technological Innovation Project for College Students in Zhejiang Province(Xinmiao Talent Plan 2022R424A005)Zhejiang Provincial Administration of Traditional Chinese Medicine(Nos.2022ZQ022,2023ZF083).
文摘Pharmacodynamics material basis and effective mechanisms are the two main issues to decipher the mechnisms of action of Traditional Chinese medicines(TCMs)for the treatment of diseases.TCMs,in“multi-component,multi-target,multi-pathway”paradigm,show satisfactory clinical results in complex diseases.New ideas and methods are urgently needed to explain the complex interactions between TCMs and diseases.Network pharmacology(NP)provides a novel paradigm to uncover and visualize the underlying interaction networks of TCMs against multifactorial diseases.The development and application of NP has promoted the safety,efficacy,and mechanism investigations of TCMs,which then reinforces the credibility and popularity of TCMs.The current organcentricity of medicine and the“one disease-one target-one drug”dogma obstruct the understanding of complex diseases and the development of effective drugs.Therefore,more attentions should be paid to shift from“phenotype and symptom”to“endotype and cause”in understanding and redefining current diseases.In the past two decades,with the advent of advanced and intelligent technologies(such as metabolomics,proteomics,transcriptomics,single-cell omics,and artificial intelligence),NP has been improved and deeply implemented,and presented its great value and potential as the next drug-discovery paradigm.NP is developed to cure causal mechanisms instead of treating symptoms.This review briefly summarizes the recent research progress on NP application in TCMs for efficacy research,mechanism elucidation,target prediction,safety evaluation,drug repurposing,and drug design.
文摘中药复方药效物质基础(material basis for efficacy of Chinese herbal formula)的是目前亟待解决的中药领域的关键问题之一,而目前对中药复方药效物质基础的界定,学术界尚有分歧。中药复方药效物质基础是某一特定复方经与人体作用后在发挥疗效的特异性的靶器官、靶组织中达到一定浓度并发挥生物学效应的直接或间接来源于该复方的非内源性活性物质的总和。中药复方药效物质基础的系统药理学评价是中药现代化和国际化的核心与基石,而中药质量控制是中药复方药效物质基础的系统药理学评价的先决条件。
